Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from EchoIQ Limited ( (AU:EIQ) ) is now available.
Echo IQ has initiated a clinical validation study for its heart failure clinical decision support software, EchoSolv HF, in collaboration with the Mayo Clinic Platform. This study, conducted with Mayo Validate, aims to evaluate EchoSolv HF’s ability to detect heart failure and is the final step before formal FDA submission. The study’s results will be crucial for Echo IQ’s FDA 510(k) application, potentially leading to market access in the US. The collaboration with Mayo Clinic Platform also allows the use of EchoSolv HF across its network, enhancing Echo IQ’s industry positioning and market reach.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.38 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
More about EchoIQ Limited
Echo IQ is an AI and medical technology company based in Sydney, Australia, specializing in AI-driven technology and proprietary software to enhance decision-making in cardiology.
Average Trading Volume: 2,934,168
Technical Sentiment Signal: Hold
Current Market Cap: A$145.2M
For a thorough assessment of EIQ stock, go to TipRanks’ Stock Analysis page.